The global supplement market, valued at nearly $50 billion, is undergoing a structural shift toward greater transparency and scientific validation, a change increasingly reflected in consumer behavior ahead of sales figures. This transformation signals a move away from marketing strategies centered on influencer promotion and broad health claims toward a more evidence-based approach.

Niagen Bioscience, a company with roots dating back more than 25 years as a provider of ingredient quality standards, exemplifies this shift. Since CEO Rob Fried took the helm in 2017, the company has concentrated exclusively on its patented nicotinamide riboside (NR) ingredient, Niagen. A vitamin B3 derivative that the body converts into nicotinamide adenine dinucleotide (NAD+), Niagen is designed to support cellular energy production and DNA repair. The company’s portfolio now includes the oral supplement Tru Niagen, pharmaceutical-grade intravenous infusions and injections for clinical settings, and the recently introduced Niagen At Home Shots telehealth service offering injectable treatments without in-person visits.

According to Mona Rosene, global director of scientific and medical affairs at Niagen Bioscience, the company emphasizes conducting its own independent research rather than relying on what it terms "borrowed science"—the practice of using clinical data from well-studied ingredients and applying it to different formulations. Niagen has conducted more than 45 human clinical trials and over 200 preclinical studies specifically on nicotinamide riboside chloride, with approximately 90% of the clinical research independently funded and involving external investigators. This approach, Rosene explains, helps reduce bias and builds credibility among consumers, healthcare providers, and researchers.

Quality control has also become a key differentiator in the supplement market. Independent testing commissioned by Niagen found that over two-thirds of NMN (nicotinamide mononucleotide) supplements examined did not meet their labeled dosage claims, with some lacking the advertised ingredients entirely. Rosene highlights the importance of transparency, noting that consumers can verify product potency and purity through publicly accessible certificates of analysis linked to each bottle's lot number. Niagen subjects its products to rigorous internal and third-party testing, a practice that newer brands may find costly to implement retroactively amid increasing regulatory scrutiny.

This emphasis on quality extends to injectable products as well. The U.S. Food and Drug Administration (FDA) has issued guidance urging clinics to use pharmaceutical-grade ingredients rather than food-grade inputs for NAD+ injections. Niagen Plus complies by using pharmaceutical-grade nicotinamide riboside chloride compounded and distributed by FDA-registered outsourcing facilities.

In an industry often plagued by misinformation and overstated claims, Rosene stresses the importance of clear, science-based communication focused on healthspan—the maintenance of health and physical function over time—rather than simply lifespan. She points out that Niagen’s clinical research concentrates on NR, which directly enters cells, unlike NAD+ and NMN that require metabolism before cellular uptake. According to Rosene, brands that prioritize credible scientific evidence tend to build stronger consumer trust and retention compared to those relying on flashy marketing and unsubstantiated claims.

Ultimately, the supplement companies that invest in proprietary research, rigorous quality assurance, and transparent communication are more likely to cultivate loyal customers who understand the specific benefits of their products. This emerging "trust era" in the supplement industry marks a departure from short-term acquisition tactics toward long-term consumer relationships built on verified science and product integrity.